JP6639364B2 - 角膜真菌症の予防または治療剤 - Google Patents

角膜真菌症の予防または治療剤 Download PDF

Info

Publication number
JP6639364B2
JP6639364B2 JP2016178997A JP2016178997A JP6639364B2 JP 6639364 B2 JP6639364 B2 JP 6639364B2 JP 2016178997 A JP2016178997 A JP 2016178997A JP 2016178997 A JP2016178997 A JP 2016178997A JP 6639364 B2 JP6639364 B2 JP 6639364B2
Authority
JP
Japan
Prior art keywords
polyethylene glycol
rapamycin
therapeutic agent
agent according
prophylactic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016178997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017057199A5 (enExample
JP2017057199A (ja
Inventor
ジンチョン チャン
ジンチョン チャン
景山　正明
正明 景山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of JP2017057199A publication Critical patent/JP2017057199A/ja
Publication of JP2017057199A5 publication Critical patent/JP2017057199A5/ja
Application granted granted Critical
Publication of JP6639364B2 publication Critical patent/JP6639364B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016178997A 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤 Expired - Fee Related JP6639364B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
US62/220,847 2015-09-18

Publications (3)

Publication Number Publication Date
JP2017057199A JP2017057199A (ja) 2017-03-23
JP2017057199A5 JP2017057199A5 (enExample) 2019-09-05
JP6639364B2 true JP6639364B2 (ja) 2020-02-05

Family

ID=58288799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016178997A Expired - Fee Related JP6639364B2 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Country Status (13)

Country Link
US (1) US10166217B2 (enExample)
EP (1) EP3351244A4 (enExample)
JP (1) JP6639364B2 (enExample)
KR (1) KR20180053340A (enExample)
CN (1) CN108025000A (enExample)
BR (1) BR112018005305A2 (enExample)
HK (2) HK1253545A1 (enExample)
MX (1) MX393608B (enExample)
MY (1) MY183906A (enExample)
PH (1) PH12018500579A1 (enExample)
SG (1) SG11201802091RA (enExample)
TW (1) TWI721015B (enExample)
WO (1) WO2017047597A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
WO2009023877A2 (en) * 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions

Also Published As

Publication number Publication date
WO2017047597A1 (ja) 2017-03-23
EP3351244A4 (en) 2019-05-01
US10166217B2 (en) 2019-01-01
SG11201802091RA (en) 2018-04-27
HK1256969A1 (en) 2019-10-04
HK1253545A1 (zh) 2019-06-21
EP3351244A1 (en) 2018-07-25
MX393608B (es) 2025-03-24
PH12018500579A1 (en) 2018-09-10
KR20180053340A (ko) 2018-05-21
TWI721015B (zh) 2021-03-11
US20180271841A1 (en) 2018-09-27
MX2018003381A (es) 2018-08-15
TW201717943A (zh) 2017-06-01
BR112018005305A2 (pt) 2018-10-09
MY183906A (en) 2021-03-17
JP2017057199A (ja) 2017-03-23
CN108025000A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
US11439652B2 (en) Ophthalmic aqueous composition
CN105073112B (zh) 睑板腺功能障碍的治疗剂
US12370209B2 (en) Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
JP6639364B2 (ja) 角膜真菌症の予防または治療剤
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
TW201518291A (zh) 含聚乙二醇之組成物
US20170304451A1 (en) Parenteral compositions of bendamustine
JP2018048134A (ja) Ｊａｋ阻害剤を含有する点眼剤
EP3369422A1 (en) External preparation
US9987368B2 (en) Pharmaceutical composition comprising polypeptide
JP2018104412A (ja) 眼疾患の治療及び／又は予防剤
TW201906597A (zh) 含有水溶性黏稠化劑之醫藥組合物
HK1238174A1 (en) Ophthalmic aqueous composition
HK1235711B (en) Ophthalmic aqueous composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190723

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190723

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191224

R150 Certificate of patent or registration of utility model

Ref document number: 6639364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees